Drugs Made In America Acquisition Corp. (DMAAR) Payables (2024 - 2026)

Drugs Made In America Acquisition (DMAAR) has reported Payables for 3 consecutive years, with $604412.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Payables rose 60341.2% year-over-year to $604412.0; the trailing twelve-month figure through Jun 2026 stood at $604412.0 (up 60341.2% YoY), and the FY2025 full-year result was $222184.0, down 69.96% from the prior year.
• Payables rose to $604412.0 in Q2 2026 per DMAAR's latest filing, from $222184.0 in the prior quarter.
• Across five years, Payables topped out at $739604.0 in Q4 2024 and bottomed at $1000.0 in Q2 2025.
• Historically, Payables has averaged $284849.7 across 3 years, with a median of $151592.0 in 2025.
• The sharpest annual moves came in 2025 and 2026: Payables tumbled 69.96% in 2025, then surged 60341.2% in 2026.
• Over 3 years, Payables stood at $739604.0 in 2024, then sank by 69.96% to $222184.0 in 2025, then surged by 172.03% to $604412.0 in 2026.
• According to Business Quant data, Payables over the past three periods registered $604412.0, $222184.0, and $81000.0 for Q2 2026, Q4 2025, and Q3 2025 respectively.